All the news Showing 8 of 28 articles from: AASLD 2016Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NAFLD When you eat may contribute to fatty liver disease as much as what you eat Liz Highleyman / 17 November 2016 People who skip breakfast and eat late at night may have an elevated risk of non-alcoholic fatty liver disease (NAFLD), according to research presented this week at the 2016 AASLD Liver Meeting in ... Pan-genotypic regimens AbbVie pangenotypic combination cures 98% or above across genotypes Keith Alcorn / 16 November 2016 AbbVie’s combination of glecaprevir and pibrentasvir cured at least 98% of people with hepatitis C in three large clinical trials covering five out of six genotypes of the virus, and is ... Pan-genotypic regimens AbbVie pangenotypic combination cures almost all hard-to-treat people with HCV genotype 3 Keith Alcorn / 16 November 2016 AbbVie’s pangenotypic combination of glecaprevir and pibrentasvir cured almost all of the hardest-to-treat genotype 3 patients – those with cirrhosis and/or previous treatment experience – in a phase II trial, and looks suitable ... Access to medicines & diagnostics US Veterans Affairs and Australia show potential for rapid elimination of hepatitis C Keith Alcorn / 15 November 2016 If sufficient money is available to pay for direct-acting antivirals (DAAs), the US Veterans Affairs (VA) could cure the majority of veterans under its care of hepatitis C within three years, and ... Antiviral therapy Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones Liz Highleyman / 15 November 2016 Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss, according to a report this ... Interferon-free regimens Grazoprevir/elbasvir + sofosbuvir highly effective for hard-to-treat genotype 3 hepatitis C patients Liz Highleyman / 14 November 2016 A triple regimen of grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hepatitis C virus (HCV) genotype 3 and liver cirrhosis, matching ... Hepatocellular carcinoma (HCC) Liver cancer risk reduced after hepatitis C treatment, but vigilance needed for aggressive cancers in months after treatment Keith Alcorn / 14 November 2016 People who are cured of hepatitis C after a course of direct-acting antiviral (DAA) treatment do not have a higher risk of developing liver cancer (hepatocellular carcinoma), and probably have a reduced ... Treatment outcomes Real-world responses to HCV treatment among US veterans match best clinical trial results Keith Alcorn / 14 November 2016 Direct-acting antiviral (DAA) treatment is curing people of hepatitis C infection in clinics at similar rates to those seen in clinical trials, and there don’t seem to be major differences between drug regimens, ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive